110 results
424B3
KPRX
Kiora Pharmaceuticals Inc
28 Mar 24
Prospectus supplement
4:48pm
cost for all commercial activities, including sales, marketing and market access.
Under the Agreement, TOI paid to us an up-front payment of $16.0 … at (858) 224-9600.
You also may access these filings on our website at www.kiorapharma.com. We do not incorporate the information on our website
8-K
EX-10.1
KPRX
Kiora Pharmaceuticals Inc
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
accountability, (iii) access to assets is permitted only in accordance with management’s general or specific authorization, and (iv) the recorded … unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse Effect; (iv
8-K
KPRX
Kiora Pharmaceuticals Inc
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
commercial activities, including sales, marketing and market access.
Under the Agreement, TOI will pay the Company an up-front payment of $16.0
8-K
EX-99.1
ep83v gwmfu0ru
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-10.1
x68m3b71i5fnhuz81mj
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.2
gwrtefsb28dmxj7
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
bjp5i9v mm3ewam
6 Nov 23
Topline Phase I/II First-in-Human Results Presented at AAO 2023
6:05am
8-K
EX-99.1
u2xqkoba mnp
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-10.2
hrd0x x2h
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
8-K
EX-1.1
iy066hw
6 Jun 23
Kiora Pharmaceuticals Announces Pricing of $5.5 Million Underwritten Public Offering
4:52pm
424B1
q19ymp62pa4 7n
2 Jun 23
Prospectus with pricing info
5:08pm
FWP
424 nkqbd7xtwyvrb9j
15 May 23
Free writing prospectus
5:18pm